The efficacy and safety of alfacalcidol in postmenopausal Chinese women with osteoporosis or osteopenia

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-11001508

Enrollment

Unknown

Registered

2011-08-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

1:1ug alfacalcidol softgel daily Daily 500 mg calcium intake will be supplemented.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: According to the WHO criterion of osteoporosis issued in 1994, inclusion of patients with osteoporosis or osteopenia with one or more non-traumatic fractures.

Exclusion criteria

Exclusion criteria: 1. Patients allergic against vitamin D or ingredients in the product; 2. Patients, who use medications, which disturb the vitamin D metabolism (e.g. glucocorticoids, immuno-suppressants, antiepileptics etc.) in 3 months before the beginning of the study; 3. According to calcium questionnaire, patients with > 800 mg calcium in the diet; 4. Patients treated with bisposphonates (alendronate, risedronate, etidronate etc.) in last 2 years.

Design outcomes

Primary

Measure	Time frame
BMD, 1,25 (OH)2D3 and i-PTH;TUG, CRT, TG;	—

Secondary

Measure	Time frame
CTX and BAL;	—

Countries

China

Contacts

Public ContactProfessor Xia Weibo

weiboxia@sohu.com+86 010 65295358

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026